Fuel metabolism, energy expenditure, and thyroid function in growth hormone-treated obese women: a double-blind placebo-controlled study.
Growth hormone (GH) promotes protein anabolism and lipolysis. Its effects on glucose metabolism include suppression of glucose oxidation and may be associated with insulin resistance. In addition, GH stimulates energy expenditure (EE) and peripheral thyroid hormone metabolism. GH secretion is reduced in obese patients, but whether this is of pathophysiological significance is incompletely understood. In a double-blind placebo-controlled crossover design, we studied the effects of GH administration (0.03 mg.kg ideal body weight [IBW]-1.d-1) on fuel metabolism, EE, and thyroid function in 10 obese women (age, 30.4 +/- 2.4 years; body mass index [BMI], 37.0 +/- 2.8 kg/m2, mean +/- SE) with a normal prestudy oral glucose tolerance test (OGTT). Each treatment period (GH or placebo) lasted 5 weeks, separated by a 5-week washout period. At the end of each treatment period, subjects were studied in the basal state (8:00 AM) and during a euglycemic glucose clamp including indirect calorimetry and isotopic measurement of glucose turnover. Lean body mass (LBM) was assessed at the end of each period by dual-energy x-ray absorptiometry. In the basal state, GH induced a significant increase in circulating levels of free fatty acids (FFA), glucose, insulin, and C-peptide. This was associated with a significant increase in resting EE (kcal/24 h, 1,934 +/- 92 placebo v 2,323 +/- 134 GH, P < .001), a decrease in the respiratory exchange ratio (RER), and increased rates of lipid oxidation (mg.kg LBM-1.min-1, 1.55 +/- 0.09 placebo v 2.20 +/- 0.13 GH, P < .01). GH increased the rate of total basal glucose turnover, whereas oxidative glucose disposal was significantly decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
University Department of Internal Medicine and Endocrinology, Aarhus Kommunehospital, Denmark.
J O
JO
Jørgensen
S B
SB
Pedersen
J
J
Børglum
N
N
Møller
O
O
Schmitz
J S
JS
Christiansen
B
B
Richelsen
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002153:Calorimetry, Indirect; D004311:Double-Blind Method; D004734:Energy Metabolism; D005260:Female; D015309:Glucose Clamp Technique; D013006:Growth Hormone / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D010919:Placebos; D011506:Proteins / Q000378:metabolism; D013961:Thyroid Gland / Q000503:physiopathology*; D013963:Thyroid Hormones / Q000097:blood
D001786:Blood Glucose; D010919:Placebos; D011506:Proteins; D013963:Thyroid Hormones; D013006:Growth Hormone